NASDAQ: MNMDMind Medicine Inc Stock
$8.46-0.41 (-4.62%)
Updated Apr 24, 2024
MNMD Price
$8.46
Fair Value Price
$2.19
Market Cap
$349.69M
52 Week Low
$2.41
52 Week High
$12.22
P/E
-3.47x
P/B
4.48x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$95.73M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.59
Operating Cash Flow
-$64M
Beta
1.51
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MNMD Overview
Mind Medicine (MindMed) Incorporated develops products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. Its MM-120 offering is in a phase 2 clinical study for the treatment of generalized anxiety disorder, attention deficit hyperactivity disorder, and chronic pain. MM-110 is an a3ß4 nicotinic cholinergic receptor antagonist that has completed aphase 1 study for the treatment of opioid withdrawal. It is also developing MM-402, a treatment for core symptoms of autism spectrum disorder. MindMed is founded in 2002 and is headquartered in Vancouver, Canada.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MNMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MNMD ($8.46) is overvalued by 287.11% relative to our estimate of its Fair Value price of $2.19 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MNMD ($8.46) is not significantly undervalued (287.11%) relative to our estimate of its Fair Value price of $2.19 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MNMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MNMD due diligence checks available for Premium users.
Be the first to know about important MNMD news, forecast changes, insider trades & much more!
MNMD News
Valuation
MNMD fair value
Fair Value of MNMD stock based on Discounted Cash Flow (DCF)
Price
$8.46
Fair Value
$2.19
Overvalued by
287.11%
MNMD ($8.46) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MNMD ($8.46) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MNMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MNMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.47x
Industry
15.69x
Market
41.27x
MNMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.48x
Industry
5.86x
MNMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MNMD's financial health
Profit margin
Revenue
$0.0
Net Income
-$23.9M
Profit Margin
0%
MNMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$124.5M
Liabilities
$46.4M
Debt to equity
0.59
MNMD's short-term assets ($103.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MNMD's short-term assets ($103.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MNMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$20.6M
Investing
$0.0
Financing
$2.6M
MNMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MNMD vs Biotech Stocks
Mind Medicine Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.